Small molecule chemopotentiator that kills multi-drug resistant cells through its interaction with P glycoprotein regulatory update

YM received a Special Protocol Assessment (SPA) from the FDA for its Phase III trial of tesmilifene to treat metastatic breast cancer. The trial, which could start in 2003, will use a sequential analy...